Clinical Trials

Infliximab in psoriasis: The EXPRESS II (Evaluation of Infliximab for Psoriasis Efficacy and Safety Study)

Infliximab for the treatment of moderate to severe psoriasis: Response to retreatment after 16 weeks or more between infusions

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here